Navigation Links
Patient Safety Technologies Completes $6.0 Million Equity Financing
Date:6/25/2010

s; risks in product development; our ability to raise capital to fund continuing operations; the ability to complete transactions; and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

Important Information

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.  The shares of convertible preferred stock have been sold pursuant to an exemption from state and federal securities laws.


'/>"/>
SOURCE Patient Safety Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
2. Emerging Markets (BRIC - Brazil, Russia, India and China): Patient Monitors 2010 - 2014
3. Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
4. Micromets Blinatumomab Induces Durable Remissions in Patients with Relapsed Non-Hodgkins Lymphoma
5. Collaborating with Patient Advocacy Groups to Educate Physicians, Patients and Thought Leaders
6. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
7. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
8. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
9. Over 205 Inches Lost by Chicago Area Patients at Complete Clinics Using Zerona(TM) Lipo Laser
10. FIRMAGON® Results in Fast, Long-Term Suppression of Testosterone in Prostate Cancer Patients Without Initial Testosterone Surge
11. Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... MALVERN, Pa. , May 29, 2015 /PRNewswire-USNewswire/ ... major focus of the Association for the Advancement ... 1995. With support from AAWC,s corporate ... Educational Portal on the AAWC website ... on a wound care pathway with links to ...
(Date:5/28/2015)... NEW YORK , May 28, 2015 ... billions developing new drugs and tests, and ... for the instruments that can assist them. This ... research publisher. Kalorama Information said instruments such as ... can assist in the identification of drug ...
(Date:5/28/2015)... , May 28, 2015  IRIDEX Corporation (NASDAQ: IRIX ... Officer James H. Mackaness is scheduled to present ... at 9:00 am PT in Los Angeles ... may be accessed on the Event Calendar of the Investors ... of the webcast will be available shortly after the conclusion ...
Breaking Medicine Technology:The Association for the Advancement of Wound Care Educates the Public 2Report: Proteomics Research Market Reaches $1.6 Billion 2Report: Proteomics Research Market Reaches $1.6 Billion 3
(Date:5/29/2015)... Healthpointe is now offering pain ... therapy, and injections , For patients throughout Southern ... back pain, Healthpointe has a team of experts ... disc protrusions and other causes of back ... of renowned surgeons are now treating osteoarthritis, spinal ...
(Date:5/29/2015)... Dr. Rodger Murphree, author of ... is now offering free weekly call in teleconferences ... ways to reduce symptoms associated with fibromyalgia including ... brain fog. , To find out more ... call in teleconferences simply go to http://www.endfibronow.com ...
(Date:5/29/2015)... 29, 2015 Healthpointe’s electromyography and ... the Los Angeles County clinics including its newest ... now being offered at all Healthpointe locations throughout ... San Bernardino County. , As the muscles ... send electrical impulses throughout the body and dictate ...
(Date:5/29/2015)... 2015 This is a professional ... the Naproxen industry.The report provides a basic overview ... industry chain structure. The Naproxen market ... development trends, competitive landscape analysis, and key regions ... well as manufacturing processes and cost structures are ...
(Date:5/29/2015)... Dallas, TX (PRWEB) May 29, 2015 ... Pipeline Review, H1 2015” provides comprehensive information ... The report strengthens R&D pipelines by identifying ... and best-in-class products. Complete report on H1 ... 18 market data tables and 13 figures, ...
Breaking Medicine News(10 mins):Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3
... 2008 (March 24), the Infectious Diseases Society of America ... U.S. policymakers to step up the fight against tuberculosis ... home and abroad. , With drug-resistant strains of TB ... on the decline, resources are needed to support TB ...
... OVERLAND PARK, Kan., March 20 A recent ... a strong reminder to,horse owners throughout the country ... mosquito-borne diseases. To ensure your horse receives,the most ... Nile-,Innovator(R)+EWT -- "The Mosquito Shot," the only vaccine ...
... Experience , KENNEBUNK, Maine, March 20 ... body care, announced a patent-pending breakthrough formula,in its ... Sensitive Care,Toothpastes., (Photo: http://www.newscom.com/cgi-bin/prnh/20080320/NETH004 ), ... cofounder & CEO of Tom,s of Maine, announced ...
... Dreier LLP (http://www.dreierllp.com ),announces that a ... District,Court for the District of Massachusetts on behalf ... the "Company"),(Nasdaq: VRTX ) publicly traded securities ... 2, 2007, inclusive (the "Class Period"). The,Complaint alleges ...
... Mass., March 20 Alseres,Pharmaceuticals, Inc. (Nasdaq: ... a,Third Amended and Restated Convertible Promissory Note Purchase ... L. Gipson, Thomas Gipson, Arthur,Koenig, Ingalls & Snyder ... "Purchaser"). The agreement provides for the Company to ...
... Response Biomedical,Corporation (TSX: RBM, OTCBB: RPBIF) today ... new state-of-the-art global headquarters located at 1781 ... March 31, 2008., The 46,000 square ... and constructed for development and GMP manufacturing,and ...
Cached Medicine News:Health News:ID, HIV experts urge more resources for TB 2Health News:Fort Dodge's 'Mosquito Shot' Offers Convenient Protection Against Dangerous Mosquito-Borne Illnesses 2Health News:Tom's of Maine Introduces a Patent-Pending New Formula with the Launch of its Natural Clean & Gentle Care and Sensitive Care Toothpastes 2Health News:Tom's of Maine Introduces a Patent-Pending New Formula with the Launch of its Natural Clean & Gentle Care and Sensitive Care Toothpastes 3Health News:Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX) 2Health News:Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX) 3Health News:Alseres Pharmaceuticals, Inc. Raises $5 Million 2Health News:Alseres Pharmaceuticals, Inc. Raises $5 Million 3Health News:Response Biomedical Corporation Moves to New Facility 2Health News:Response Biomedical Corporation Moves to New Facility 3Health News:Response Biomedical Corporation Moves to New Facility 4
The Bio-Quant CK-MB test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of,CK-MB in human serum specimens as an aid in the diagnosis of myocar...
... an all new, completely re-engineered high performance PTCA ... LOWEST CROSSING PROFILE PTCA products available at ... of only 0.17. Atriums all new HyperLite LX ... ever!, ,Atriums new "Dura-Blend tip technology is a ...
... Through its unique and patented design, ... and trunk cables between patients and ... allowing freedom of movement throughout the ... the LifeSync(R) System employs two-way radios ...
... in vitro assay for detection of alpha ... is a protein with molecular mass ranging ... concentration in serum is below 9 ng/mL; ... ovarian, testicular and presacral teratocarcinomas, and other ...
Medicine Products: